# Updates on Diphenidine Scheduling in Controlled Substances > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-scheduling-update-schedule-i-placement/ > **Published:** 2026-06-18T01:07:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:24:18-04:00 > **Clinical Summary:** Learn about the latest diphenidine scheduling update and its placement in Schedule I under the Controlled Substances Act. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation Clinical Summary The Drug Enforcement Administration has placed diphenidine, a synthetic dissociative drug, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its high abuse potential and lack of accepted medical use. Diphenidine is a structural analog of methoxetamine and other dissociative compounds that have emerged as drugs of abuse, particularly in online markets, with reported effects similar to phencyclidine and ketamine. This scheduling action reflects the DEA’s response to novel psychoactive substances that pose [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) risks, though it does not directly impact [cannabis regulation](https://cedclinic.com/marijuana-rescheduling-regulatory-updates-march-2026/) or [clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) prescribing practices. Clinicians should be aware that dissociative drug abuse, including synthetic analogs like diphenidine, may present in patients as acute psychiatric symptoms, altered consciousness, or substance use disorder requiring appropriate screening and intervention. The practical takeaway for clinicians is to maintain awareness of emerging synthetic drugs and their potential to complicate the clinical picture in patients presenting with dissociative symptoms, while recognizing that cannabis and dissociative drugs represent distinct pharmacological classes with different regulatory and clinical profiles. Clinical Perspective 🧠 The recent scheduling of diphenidine as a Schedule I controlled substance reflects ongoing regulatory efforts to address novel synthetic drugs that emerge faster than formal safety data can accumulate. Diphenidine, a dissociative compound chemically similar to ketamine and phencyclidine, poses particular challenges because its abuse potential and adverse effects in humans remain poorly characterized despite growing recreational use. Clinicians should be aware that patients presenting with dissociative symptoms, altered consciousness, or behavioral changes may have used synthetic dissociatives like diphenidine through illicit channels, and standard urine drug screening will not detect these agents. The rapid evolution of the designer drug landscape means that scheduling actions often follow rather than precede clinical encounters with these substances, leaving providers with limited evidence about treatment approaches and long-term consequences. Healthcare providers should maintain a high index of suspicion for novel synthetic drug use when patients present with dissociative or sympathomimetic toxi 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Policy Watch: 5 Regulatory Updates — June 17, 2026](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-2026/) - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Temporary Placement of 2-Fluorodeschloroketamine in Schedule I 📰 Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence Schedules of Controlled Substances: Placement of Diphenidine in Schedule I Explore detailed information on the placement of diphenidine in Schedule I and its regulatory context. Read More Schedules of Controlled Substances: Placement of Diphenidine in Schedule I Review additional insights on diphenidine’s scheduling and implications for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Learn More [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) Understand related scheduling actions for synthetic dissociatives including 2-Fluorodeschloroketamine. [Explore Now](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).